Engineers Gate Manager LP Mersana Therapeutics, Inc. Transaction History

Engineers Gate Manager LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.11 - $2.34 $20,652 - $43,538	18,606 Added 74.16%	43,694 $101,000
Q3 2023 Nov 14, 2023	SELL	$1.06 - $3.91 $16,591 - $61,199	-15,652 Reduced 38.42%	25,088 $31,000
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $87,533 - $271,411	-28,420 Reduced 41.09%	40,740 $134,000
Q1 2023 May 15, 2023	BUY	$4.0 - $7.02 $52,632 - $92,369	13,158 Added 23.5%	69,160 $284,000
Q4 2022 Feb 14, 2023	SELL	$5.65 - $7.86 $14,113 - $19,634	-2,498 Reduced 4.27%	56,002 $328,000
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $270,855 - $468,000	58,500 New	58,500 $395,000
Q2 2022 Aug 15, 2022	SELL	$2.84 - $5.0 $28,763 - $50,640	-10,128 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.74 - $6.63 $38,791 - $68,766	-10,372 Reduced 50.6%	10,128 $40,000
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $112,340 - $202,130	20,500 New	20,500 $128,000
Q3 2021 Nov 15, 2021	SELL	$8.56 - $14.47 $373,147 - $630,776	-43,592 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $421,400 - $573,397	31,732 Added 267.55%	43,592 $592,000
Q1 2021 May 17, 2021	BUY	$15.31 - $26.52 $181,576 - $314,527	11,860 New	11,860 $192,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.